Sign in or create an account to add this stock to your watchlist.
About Kamada (NASDAQ:KMDA)
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD). It also provides immunoglobulin products that comprise KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company offers other products, including Heparin Lock Flush to maintain patency of indwelling IV catheter; Kamacaine 0.5% used as anesthesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Human Transferrin, which is used as a cultural medium for diagnostic assays and cell cultures. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. Additionally, it provides Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of blood plasma. Kamada Ltd. also offers coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Baxter International Inc.; Chiesi Farmaceutici; PARI GmbH; and Kedrion S.p.A. The company was founded in 1990 and is headquartered in Rehovot, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472
Debt
Debt-to-Equity Ratio0.01
Current Ratio3.47
Quick Ratio2.58
Price-To-Earnings
Trailing P/E Ratio27.22
Forward P/E Ratio21.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$102.82 million
Price / Sales1.92
Cash Flow$0.2584 per share
Price / Cash18.96
Book Value$2.24 per share
Price / Book2.19
Profitability
EPS (Most Recent Fiscal Year)$0.18
Net Income$6.90 million
Net Margins11.17%
Return on Equity14.64%
Return on Assets10.67%
Miscellaneous
Employees377
Outstanding Shares40,260,000
Kamada (NASDAQ:KMDA) Frequently Asked Questions
What is Kamada's stock symbol?
Kamada trades on the NASDAQ under the ticker symbol "KMDA."
How were Kamada's earnings last quarter?
Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported $0.03 earnings per share for the quarter, hitting the consensus estimate of $0.03. The biotechnology company earned $17.44 million during the quarter, compared to the consensus estimate of $24.89 million. Kamada had a net margin of 11.17% and a return on equity of 14.64%. View Kamada's Earnings History.
When is Kamada's next earnings date?
What price target have analysts set for KMDA?
3 equities research analysts have issued 1 year target prices for Kamada's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Kamada's share price to reach $7.00 in the next twelve months. View Analyst Ratings for Kamada.
Who are some of Kamada's key competitors?
Some companies that are related to Kamada include Rocket Pharmaceuticals (RCKT), Dova Pharmaceuticals (DOVA), GlycoMimetics (GLYC), Amphastar Pharmaceuticals (AMPH), Vectura Group (VEGPF), ANI Pharmaceuticals (ANIP), CymaBay Therapeutics (CBAY), NuCana (NCNA), Homology Medicines (FIXX), Dicerna Pharmaceuticals (DRNA), Arcus Biosciences (RCUS), Rigel Pharmaceuticals (RIGL), Five Prime Therapeutics (FPRX), Odonate Therapeutics (ODT) and Ziopharm Oncology (ZIOP).
Who are Kamada's key executives?
Kamada's management team includes the folowing people:
- Mr. Amir London, Chief Exec. Officer (Age 49)
- Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 67)
- Dr. Liliana Bar, VP of R&D & IP (Age 63)
- Mr. Chaime Orlev, Chief Financial Officer (Age 48)
- Mr. Eran Nir, VP of Operations & Plant Mang. (Age 45)
Has Kamada been receiving favorable news coverage?
News coverage about KMDA stock has been trending somewhat positive on Monday, according to Accern Sentiment. Accern identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kamada earned a daily sentiment score of 0.13 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.30 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Kamada's major shareholders?
Which major investors are selling Kamada stock?
How do I buy shares of Kamada?
Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kamada's stock price today?
One share of KMDA stock can currently be purchased for approximately $4.90.
How big of a company is Kamada?
Kamada has a market capitalization of $197.29 million and generates $102.82 million in revenue each year. The biotechnology company earns $6.90 million in net income (profit) each year or $0.18 on an earnings per share basis. Kamada employs 377 workers across the globe.
How can I contact Kamada?
Kamada's mailing address is 7 SAPIR STREET KIRYAT WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7414002. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]
MarketBeat Community Rating for Kamada (KMDA)
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kamada (NASDAQ:KMDA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Kamada in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 42.86%. The high price target for KMDA is $7.00 and the low price target for KMDA is $7.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $7.00 | $7.00 | $8.50 |
| Price Target Upside: | 42.86% upside | 35.92% upside | 35.92% upside | 75.26% upside |
Kamada (NASDAQ:KMDA) Consensus Price Target History
Kamada (NASDAQ:KMDA) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Kamada (NASDAQ:KMDA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Kamada (NASDAQ KMDA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 9.42%
Kamada (NASDAQ KMDA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Kamada (NASDAQ KMDA) News Headlines
| Source: |
|
Kamada (NASDAQ:KMDA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kamada (NASDAQ:KMDA) Income Statement, Balance Sheet and Cash Flow Statement
Kamada (NASDAQ KMDA) Stock Chart for Monday, May, 21, 2018
Loading chart…
